Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19

[1]  T. Choueiri,et al.  Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium , 2023, The Lancet Regional Health - Americas.

[2]  M. Kiso,et al.  Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB , 2022, The New England journal of medicine.

[3]  Bethany M. Kwan,et al.  Referrals, access, and equity of monoclonal antibodies for outpatient COVID-19: A qualitative study of clinician perspectives , 2022, Medicine.

[4]  T. Choueiri,et al.  Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. , 2022, JAMA oncology.

[5]  S. Tulledge-Scheitel,et al.  Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch , 2022, Open forum infectious diseases.

[6]  V. Mastey,et al.  Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19 , 2022, Infectious Diseases and Therapy.

[7]  D. Farmakiotis,et al.  mRNA Vaccination Decreases COVID-19-Associated Morbidity and Mortality Among Organ Transplant Recipients: A Contemporary Cohort Study , 2022, Open forum infectious diseases.

[8]  L. Pickering,et al.  Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer , 2022, Cell Reports Medicine.

[9]  Mark Howison,et al.  SARS-CoV-2 Variants in Rhode Island; May 2022 Update. , 2022, Rhode Island medical journal.

[10]  H. van Bakel,et al.  Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants , 2022, The New England journal of medicine.

[11]  H. Ellidokuz,et al.  Effects of SARS-CoV-2 infections in patients with cancer on mortality, ICU admission and incidence: a systematic review with meta-analysis involving 709,908 participants and 31,732 cancer patients , 2022, Journal of Cancer Research and Clinical Oncology.

[12]  Shaolei Lu,et al.  Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies , 2022, Cancer.

[13]  M. Robson,et al.  Factors Associated With Cancer Treatment Delay Among Patients Diagnosed With COVID-19 , 2022, JAMA network open.

[14]  S. Arora,et al.  Current Effective Therapeutics in Management of COVID-19 , 2022, Journal of clinical medicine.

[15]  R. Chemaly,et al.  How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies , 2022, Blood.

[16]  D. Farmakiotis.  COVID-19 Treatments for Nonhospitalized Patients. , 2022, JAMA.

[17]  A. Cathcart,et al.  Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2022, JAMA.

[18]  Francisco Martín-Rodríguez,et al.  One-on-one comparison between qCSI and NEWS scores for mortality risk assessment in patients with COVID-19 , 2022, Annals of medicine.

[19]  R. Hájek,et al.  Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience , 2022, Hematological oncology.

[20]  J. Warner,et al.  Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. , 2021, Cancer discovery.

[21]  Y. Shyr,et al.  COVID-19 vaccination and breakthrough infections in patients with cancer , 2021, Annals of Oncology.

[22]  L. Philpot,et al.  Reply to Puing et al , 2021, The Journal of infectious diseases.

[23]  Shaolei Lu,et al.  Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease. , 2021, JAMA oncology.

[24]  Ryan J. Anderson,et al.  Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab among High-Risk Patients with Mild to Moderate Coronavirus Disease 2019 , 2021, The Journal of infectious diseases.

[25]  D. Skovronsky,et al.  Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 , 2021, The New England journal of medicine.

[26]  E. Robilotti,et al.  Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19 , 2021, JAMA oncology.

[27]  J. Warner,et al.  Care without a compass: Including patients with cancer in COVID-19 studies , 2021, Cancer Cell.

[28]  D. Skovronsky,et al.  Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[29]  F. Polack,et al.  Prevention of severe COVID-19 in the elderly by early high-titer plasma therapy , 2021, The New England Journal of Medicine.

[30]  G. Atwal,et al.  Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies , 2020, Science.

[31]  Alokkumar Jha,et al.  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.